An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

289

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

September 23, 2021

Study Completion Date

February 9, 2022

Conditions
Psoriasis
Interventions
DRUG

Apremilast

Oral

OTHER

Placebo

Oral

Trial Locations (52)

1000

Centre Hospitalier Universitaire Saint Pierre, Brussels

1200

Cliniques Universitaires St Luc, Brussels

3000

UZ Leuven, Leuven

10789

ISA - Interdisciplinary Study Association GmbH, Berlin

11790

Stony Brook Dermatology Associates, Stony Brook

19103

Paddington Testing Company Inc, Philadelphia

23502

Virginia Clinical Research Inc, Norfolk

23538

Universitaetsklinikum Schleswig-Holstein, Campus Luebeck, Lübeck

26505

Dermatology Center for Skin Health, Morgantown

27262

Dermatology Consulting Services, High Point

31000

Larrey University Hospital, Toulouse

31217

Skin Care Physicians of Georgia, Macon

33073

Glick Skin Institute, Margate

33144

International Dermatology Research, Inc, Miami

33604

Centre Hospitalier Universitaire (CHU) de Bordeaux - Hopital Saint-Andre, Pessac

34125

Azienda Sanitaria Universitaria Integrata di Trieste, Trieste

35128

Azienda Ospedaliera Di Padova, Padua

35233

University of Alabama at Birmingham, Birmingham

43230

Ohio State University Medical Center, Gahanna

45701

Oakview Dermatology, Athens

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

53127

Universitaetsklinikum Bonn, Bonn

55101

Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Mainz

58100

Presidio Ospedaliero della Misericordia, Grosseto

59037

Hopital Claude Huriez CHRU Lille, Lille

60020

Ospedali Riuniti di Ancona, Ancona

60590

Universitatsklinikum Frankfurt, Frankfurt am Main

66211

Adult and Pediatric Dermatology, Overland Park

67100

Azienda Sanitaria Locale 1 Ospedale Regionale San Salvatore, LAquila

77004

Center for Clinical Studies, Houston

78660

Austin Institute for Clinical Research, Pflugerville

89052

J Woodson Dermatology and Associates, Henderson

89124

Azienda Ospedaliera Bianchi Melacrino Morelli, Reggio Calabria

89144

Las Vegas Dermatology, Las Vegas

90404

Clinical Science Institute, Santa Monica

91054

Hautklinik Universitatsklinikum Erlangen, Erlangen

92708

First OC Dermatology, Fountain Valley

97239

Oregon Health and Science University, Portland

98004

Bellevue Dermatology Clinic, Bellevue

01915

ActivMed Practices and Research Inc, Beverly

02115

Brigham and Womens Hospital, Boston

03766

Dartmouth Hitchcock Medical Center, Lebanon

03801

ActivMed, Portsmouth

02919

Clinical Partners LLC, Johnston

N6A 3H7

Guenther Dermatology Research Centre, London

L3P1X2

Lynderm Research Inc, Markham

N2J 1C4

K Papp Clinical Research, Waterloo

J7Z 7E2

Dre Angelique Gagne-Henley M.D. Inc, Saint-Jérôme

A1E 1V4

Skincare Studio, St. John's

06202

CHU de Nice Archet I, Nice

04019

Universita degli Studi di Roma La Sapienza Ospedale A Fiorini di Terracina, Terracina

00917

GCM Medical Group, PSC, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03777436 - An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis | Biotech Hunter | Biotech Hunter